- Q1 2024 Nanobiotix SA Earnings Call TranscriptMay 22, 2024€5.41 (-13.93%)Earnings
- Nanobiotix SA 65th ASTRO Annual Meeting 2023 TranscriptOct 05, 2023
- Half Year 2023 Nanobiotix SA Earnings Call TranscriptSep 27, 2023€8 (+0.38%)Earnings
- Nanobiotix SA at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Nanobiotix SA License Agreement with Janssen Briefing TranscriptJul 10, 2023
- Q4 2022 Nanobiotix SA Earnings Call TranscriptApr 25, 2023€2.5 (-27.26%)Earnings
- Nanobiotix SA at Evercore ISI HealthCONx Conference (Virtual) TranscriptDec 01, 2022
- Nanobiotix SA at Jefferies London Healthcare Conference TranscriptNov 15, 2022
- Q3 2022 Nanobiotix SA Earnings Call TranscriptNov 10, 2022€3.68 (-1.87%)Earnings
- Q2 2022 Nanobiotix SA Earnings Call TranscriptSep 29, 2022€3.5 (-0.43%)Earnings
- Nanobiotix SA at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Q1 2022 Nanobiotix SA Earnings Call TranscriptMay 19, 2022€5.18 (+0.58%)Earnings
- Q4 2021 Nanobiotix SA Earnings Call TranscriptMar 31, 2022Earnings
Q2 2022 Nanobiotix SA Earnings Call Transcript
Good afternoon and good morning, and welcome to Nanobiotix conference call to discuss our first-half 2022 financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder, and Chief Executive Officer; and Bart Van Rhijn, Chief Financial Officer.
As a reminder, today's call is being webcast and will be available on our website for replay. I would like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success, and timing of our ongoing and planned clinical trials, collaborations, regulatory filings, data presentation, and future research and development efforts among other things.
These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. They are subject to significant risks and uncertainties that could cause the company's actual results to differ materially from our current expectations. Accordingly, you're cautioned not to place undue reliance on forward-looking statements.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)